Maravai Lifesciences Holdings earnings release, May 7, 2026
MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
First quarter 2026 total revenue up 41% from prior year
Base revenue excluding revenue for high-volume CleanCap for commercialized COVID-19 vaccines up 10% from prior year
SAN DIEGO, Calif., — May 7, 2026 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates.
Key Financial Results:
• Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million;
• Returned to positive free cash flow, generating $4.2 million in the quarter; and
• Increased full year 2026 Revenue and Adjusted EBITDA guidance.
“2026 is off to a strong start, driven by improving demand in our core TriLink base business and continued strength across our higher-margin portfolio,” said Bernd Brust, CEO of Maravai LifeSciences. “TriLink base, non-COVID revenue grew 15% year over year, while total TriLink revenue grew 65%. Our disciplined focus on the cost structure and operational efficiency translated this revenue growth into meaningful EBITDA expansion and positive free cash flow, reflecting the structural improvements taking hold across the business.”
Brust continued, “With solid first quarter performance and improving visibility into the balance of the year, we are raising our full-year revenue and EBITDA guidance. We remain confident in our strategy to drive sustained, profitable growth and long-term value creation.”
Revenue for the First Quarter 2026
First Quarter 2026 Financial Results by Reporting Segment
Revenue for the first quarter was $65.8 million, an increase of 40.5% compared to the prior year period, driven by the following:
• TriLink revenue was $47.5 million, increasing 65.1% year-over-year, primarily driven by $14.3 million of high-volume CleanCap orders for commercial phase COVID vaccine programs. Excluding
COVID CleanCap revenue, TriLink base revenue grew 15.4% year-over-year with strength in both Discovery and GMP consumables.
• Cygnus revenue was $18.4 million, increasing 1.4% year-over-year, driven by strong demand in North America and EMEA, partially offset by lower contribution from China due to distributor ordering timing.
Net loss and Adjusted EBITDA (non-GAAP) were $(6.4) million and $20.3 million, respectively, for the first quarter of 2026, compared to net loss and Adjusted EBITDA (non-GAAP) of $(52.9) million and $(10.5) million, respectively, for the first quarter of 2025.
Updated Financial Guidance for Full Year 2026
Financial statements
Income Statement
Three Months Ended March 31, — Revenue for the First Quarter 2026
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | Three Months Ended March 31, – Year-over-Year % Change | |
|---|---|---|---|
| TriLink | 47,476 | 28,750 | 65.1% |
| Cygnus | 18,361 | 18,100 | 1.4% |
| Total Revenue | 65,837 | 46,850 | 40.5% |
Income Statement
Three Months Ended March 31, — (Unaudited)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Revenue | 65,837 | 46,850 | |
| Cost of revenue | 32,136 | 39,125 | |
| Gross profit | 33,701 | 7,725 | |
| Operating expenses: | Selling, general and administrative | 29,092 | 39,564 |
| Operating expenses: | Research and development | 3,889 | 4,888 |
| Operating expenses: | Goodwill impairment | 12,435 | |
| Operating expenses: | Restructuring | 2,878 | |
| Operating expenses: | Total operating expenses | 35,859 | 56,887 |
| Operating expenses: | Loss from operations | -2,158 | -49,162 |
| Other income (expense): | Interest expense | -5,749 | -6,778 |
| Other income (expense): | Interest income | 1,873 | 3,225 |
| Other income (expense): | Other (expense) income | -494 | 24 |
| Other income (expense): | Loss before income taxes | -6,528 | -52,691 |
| Other income (expense): | Income tax (benefit) expense | -151 | 162 |
| Other income (expense): | Net loss | -6,377 | -52,853 |
| Other income (expense): | Net loss attributable to non-controlling interests | -2,644 | -22,908 |
| Other income (expense): | Net loss attributable to Maravai LifeSciences Holdings, Inc. | -3,733 | -29,945 |
| Other income (expense): | Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted | -0.02 | -0.21 |
| Other income (expense): | Weighted average number of Class A common shares outstanding, basic and diluted | 146,426 | 143,425 |
Income Statement
(Unaudited)
| Net Loss to Adjusted EBITDA (non-GAAP) – Three Months Ended March 31, – 2026 | Net Loss to Adjusted EBITDA (non-GAAP) – Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Net loss | -6,377 | -52,853 | |
| Add: | Amortization | 6,472 | 7,030 |
| Add: | Depreciation | 4,900 | 5,693 |
| Add: | Interest expense | 5,749 | 6,778 |
| Add: | Interest income | -1,873 | -3,225 |
| Add: | Income tax (benefit) expense | -151 | 162 |
| Add: | EBITDA | 8,720 | -36,415 |
| Add: | Acquisition integration costs (1) | 231 | 767 |
| Add: | Stock-based compensation (2) | 6,743 | 10,403 |
| Add: | Merger and acquisition related expenses (3) | 1,178 | |
| Add: | Goodwill impairment (4) | 12,435 | |
| Add: | Restructuring costs (5) | 3,110 | |
| Add: | Other (6) | 1,523 | 1,083 |
| Add: | Adjusted EBITDA (non-GAAP) | 20,327 | -10,549 |
Income Statement
(Unaudited)
| Net Loss attributable to Maravai LifeSciences Holdings, Inc. to Adjusted Net Income (Loss) (non-GAAP) and Adjusted Fully Diluted Earnings (Loss) Per Share (non-GAAP) – Three Months Ended March 31, – 2026 | Net Loss attributable to Maravai LifeSciences Holdings, Inc. to Adjusted Net Income (Loss) (non-GAAP) and Adjusted Fully Diluted Earnings (Loss) Per Share (non-GAAP) – Three Months Ended March 31, – 2025 | |
|---|---|---|
| Net loss attributable to Maravai LifeSciences Holdings, Inc. | -3,733 | -29,945 |
| Net loss impact from pro forma conversion of Class B shares to Class A common shares | -2,644 | -22,908 |
| Adjustment to the provision for income tax (7) | 647 | 5,456 |
| Tax-effected net loss | -5,730 | -47,397 |
| Acquisition integration costs (1) | 231 | 767 |
| Stock-based compensation (2) | 6,743 | 10,403 |
| Merger and acquisition related expenses (3) | 1,178 | |
| Goodwill impairment (4) | 12,435 | |
| Restructuring costs (5) | 3,110 | |
| Other (6) | 1,523 | 1,083 |
| Tax impact of adjustments (8) | -2,040 | 1,095 |
| Adjusted net income (loss) (non-GAAP) | 3,837 | -20,436 |
| Diluted weighted average shares of Class A common stock outstanding | 261,679 | 255,457 |
| Adjusted net income (loss) (non-GAAP) | 3,837 | -20,436 |
| Adjusted fully diluted earnings (loss) per share (non-GAAP) | 0.01 | -0.08 |
Cash Flow
| Free Cash Flow (non-GAAP) – Three Months Ended March 31, – 2026 | Free Cash Flow (non-GAAP) – Three Months Ended March 31, – 2025 | |
|---|---|---|
| Net cash provided by (used in) operating activities | 8,665 | -9,390 |
| Purchases of property and equipment | -4,437 | -4,501 |
| Free cash flow (non-GAAP) | 4,228 | -13,891 |
Full release
Maravai’s financial guidance for the full year 2026 is based on expectations for its existing business and does not include the financial impact of potential new acquisitions, if any, or items that have not yet been identified or quantified. This guidance is also subject to a number of risks, uncertainties and other factors, including those identified in “Forward-looking Statements” below.
Revenue for the full year 2026 is now expected to be in the range of $205.0 million to $215.0 million, up from the prior range of $200.0 million to $210.0 million.
Adjusted EBITDA (non-GAAP) is now expected to be in the range of $30.0 million to $32.0 million, up from the prior range of $18.0 million to $20.0 million.
As it relates to forward-looking Adjusted EBITDA, Maravai cannot provide guidance for the most directly comparable GAAP measure or a reconciliation of this non-GAAP financial measure because it is unable to provide a meaningful or accurate calculation or estimation of certain significant reconciling items without unreasonable effort.
Conference Call and Webcast
Maravai’s management will host a conference call today at 2:00 p.m. PT/ 5:00 p.m. ET to discuss its financial results for the first quarter of 2026 and other business updates. To participate in the conference call by telephone, approximately 10 minutes before the call, dial 1-800-343-5172 or 1-203-518-9856 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com/.